Ambys Medicines
Stephen Strom, Ph.D. completed his medical training at the University of Kansas Medical Center. He is a Professor at the Karolinska Institutet in the Department of Laboratory Medicine of the Division of Pathology, Stockholm, Sweden. He also holds a joint appointment in the Division of Cellular and Molecular Pathology at the University of Pittsburgh. Stephen is the Torsten och Ragnar Söderberg Professor in Cell Transplantation and Regenerative Medicine. At the Karolinska Institutet, he is the principal investigator for a Strategic Research Program in Cancer (StratCan) and the Vetenskapsrådet (Swedish Research Council) study entitled, “Understanding the biology of genes associated with longevity and healthy aging using humanized mouse models.” His work also includes a European Commission study entitled, “HUMAN: Health and understanding of metabolism, aging, and nutrition.” Stephen’s research interests include hepatocyte transplantation as a clinical treatment of liver disease, expression and regulation of drug-metabolizing enzymes in the human liver, regulation of human hepatocyte replication and differentiation, and production of hepatocytes for transplantation from the stem or progenitor cells.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.